Please visit answersincme.com/WWD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter Lio, MD, FAAD; Sarah L. Chamlin, MD; and Heather Moery. In this activity, experts in pediatric atopic dermatitis discuss earlier use of systemic therapy to improve long-term disease control and patient-centered outcomes. Upon completion of this activity, participants should be better able to: Identify the need for systemic therapy among pediatric patients with moderate-to-severe atopic dermatitis (AD); Recognize pediatric patients with moderate-to-severe AD for whom biologic therapy is an appropriate, evidence-based option; Review shared decision-making considerations regarding biologic therapy for pediatric patients with moderate-to-severe AD; and Integrate strategies to optimize biologic treatment for pediatric patients with moderate-to-severe AD.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related